Key Developments: Apricus Biosciences Inc (APRI.O)

APRI.O on Consolidated Issue listed on NASDAQ Capital Market

2.36USD
24 Apr 2014
Price Change (% chg)

$-0.02 (-0.84%)
Prev Close
$2.38
Open
$2.34
Day's High
$2.40
Day's Low
$2.28
Volume
98,630
Avg. Vol
289,311
52-wk High
$3.49
52-wk Low
$1.66

Search Stocks

Latest Key Developments (Source: Significant Developments)

Apricus Biosciences Inc announces national phase approval for Vitaros in Spain
8:00am EDT 

Apricus Biosciences Inc:Spanish Agency for Medicines and Health Products has granted national phase approval to Vitaros, Apricus' novel topical on-demand treatment for erectile dysfunction.With approval in Spain, Company has now received total of ten national phase approvals for Vitaros.  Full Article

Apricus Biosciences Inc and Recordati sign exclusive license agreement to market topical erectile dysfunction cream
Monday, 10 Feb 2014 07:00am EST 

Apricus Biosciences Inc:Signs exclusive license agreement with Recordati S.p.A. to market Vitaros, its topical on-demand product for the treatment of erectile dysfunction (ED), in Spain, Russia, Turkey, Ireland and certain other European and African countries.Under the terms of the agreement, Apricus is eligible to receive up to about $3.8 million from Recordati in upfront and pre-commercialization milestone payments.Apricus is also eligible to receive up to about $47 million in sales milestone payments, plus double-digit tiered royalties based on Recordati's net sales of the product in the Territory.  Full Article

Apricus Biosciences Inc elects Kleanthis G. Xanthopoulos, Ph.D. as new chairman
Wednesday, 11 Dec 2013 07:00am EST 

Apricus Biosciences Inc:Says Kleanthis G. Xanthopoulos, Ph.D. has been elected as chairman of the company's Board of Directors.Says Xanthopoulos succeeds Rusty Ray in the Chairman role.Says Ray will continue to serve as a Director and will assume key roles on the company's audit, compensation and corporate governance committees of the Board.Says Xanthopoulos has been a member of the Apricus Board since 2011.  Full Article

Apricus Biosciences Inc announces national phase approval for erectile dysfunction cream vitaros in italy
Monday, 25 Nov 2013 04:41pm EST 

Apricus Biosciences Inc:Says Italian Medicines Agency (AIFA) has granted national phase approval to Vitaros, indicated for the treatment of patients with erectile dysfunction (ED).Says the company has received a total of six national phase approvals for Vitaros, including Germany, Ireland, Italy, the Netherlands, Sweden and the United Kingdom.  Full Article

Apricus Biosciences Inc Receives Marketing Approval for Vitaros
Monday, 10 Jun 2013 07:00am EDT 

Apricus Biosciences Inc announced that its marketing application for Vitaros, indicated for the treatment of patients with erectile dysfunction ('ED'), has been approved through the European Decentralized Procedure ('DCP'). Under the DCP, Apricus filed its application for marketing approval designating Netherlands as the Reference Member State ('RMS') on behalf of nine other European Concerned Member States ('CMS') participating in the procedure. The CMS include France, Germany, Italy, UK, Ireland, Spain, Sweden, Belgium and Luxembourg. The Company will continue to work independently as well as with its commercialization partners, Sandoz, Takeda, and Bracco for the next step of obtaining national phase approvals in order to make Vitaros ready to launch in each of the included territories across Europe.  Full Article

Apricus Biosciences Inc Prices $17.1 Million Public Offering Of Common Stock And Warrants
Thursday, 23 May 2013 09:15am EDT 

Apricus Biosciences Inc announced that it has priced an underwritten public offering of an aggregate of 6,000,000 shares of common stock at a price to the public of $2.85 per share, and warrants to purchase up to an aggregate of 3,000,000 shares of common stock for gross offering proceeds of $17,100,000. The shares of common stock and warrants are immediately separable and will be issued separately. The warrants are exercisable immediately upon issuance, have a five-year term and an exercise price of $3.40 per share. In addition, Apricus Bio has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock and warrants to purchase up to an additional 450,000 shares of common stock to cover over-allotments, if any. The net offering proceeds to Apricus Bio from this offering are expected to be approximately $15.8 million, after deducting underwriting discounts and commissions and other estimated offering expenses, but excluding the exercise of any warrants and any exercise of the underwriters' over-allotment option. The offering is expected to close on or about May 29, 2013, subject to customary closing conditions. Lazard Capital Markets LLC is acting as sole book-running manager for the offering and Roth Capital Partners, LLC and Cantor Fitzgerald & Co. are acting as co-managers for the offering.  Full Article

Apricus Biosciences Inc Announces Proposed Public Offering of Common Stock and Warrants
Wednesday, 22 May 2013 04:01pm EDT 

Apricus Biosciences Inc announced that it intends to offer shares of common stock and warrants in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock and warrants to cover over-allotments, if any. Lazard Capital Markets LLC is acting as sole book-running manager for the offering. While the offering is expected to price before 9:30 am EDT on May 23, 2013, the offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  Full Article

Apricus Biosciences Inc Announces Sale Of Non-Core Assets
Monday, 1 Apr 2013 04:00pm EDT 

Apricus Biosciences Inc announced that the sale of (1) Totect (dexrazoxane HCl), a marketed, injectable treatment for anthracycline extravasation, and (2) NitroMist (nitroglycerin sublingual aerosol), an FDA-approved nitrate vasodilator indicated for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. In line with its previously stated corporate strategy, the Company is focusing its resources on commercializing its lead product Vitaros (alprostadil 0.3% topical cream), for the treatment of erectile dysfunction (ED), and on the development of Femprox (alprostadil 0.4% topical cream), for the treatment of female sexual arousal disorder (FSAD). Totect was acquired by Biocodex USA (Biocodex), a subsidiary of a privately-held, French pharmaceutical company, Biocodex Laboratories. Under terms of the Biocodex agreement, Apricus Bio received an upfront payment at closing and is eligible to receive royalties on net sales of Totect by Biocodex through 2016, in exchange for Apricus Bio's sale of its commercialization rights to Totect in North America and South America. NitroMist was acquired by Mist Pharmaceuticals, LLC (Mist), a privately held specialty pharmaceutical company. Mist will receive rights to commercialize and market NitroMist in all countries outside the U.S., Canada and Mexico.  Full Article

Apricus Biosciences Inc Appoints Richard W. Pascoe as Chief Executive Officer
Monday, 18 Mar 2013 11:00am EDT 

Apricus Biosciences Inc announced the appointment of Richard W. Pascoe as Chief Executive Officer(CEO) of the Company, effective March 18, 2013. In addition to his role as CEO, he has also joined the Company's Board of Directors. With Mr. Pascoe's appointment, Steve Martin, Interim CEO, will resume his responsibilities as Senior Vice President and Chief Financial Officer.  Full Article

Apricus Biosciences Inc Announces Management Changes
Tuesday, 6 Nov 2012 05:36pm EST 

Apricus Biosciences Inc announced that Bassam Damaj, has resigned as a Director, President, and Chief Executive Officer of the Company and that Steve Martin, Senior Vice President and Chief Financial Officer, has been appointed interim Chief Executive Officer. The changes are effective immediately. The Company also announced that Board of Directors has retained an executive recruiting firm to assist in identifying a permanent Chief Executive Officer whose experience is expected to include background in commercial operations within the pharmaceutical industry.  Full Article

Search Stocks